Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ixazomib
Drug ID BADD_D01223
Description Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Indications and Usage Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Marketing Status approved; investigational
ATC Code L01XG03
DrugBank ID DB09570
KEGG ID D10130
MeSH ID C548400
PubChem ID 25183872
TTD Drug ID Not Available
NDC Product Code 63020-078; 63020-400; 63020-230; 63020-079; 63020-080; 63020-390
UNII 71050168A2
Synonyms ixazomib | MLN 9708 | MLN9708 | MLN-9708 | Ninlaro
Chemical Information
Molecular Formula C14H19BCl2N2O4
CAS Registry Number 1072833-77-2
SMILES B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal disorder20.01.02.0020.000582%Not Available
Renal pain20.02.03.0030.000246%Not Available
Respiratory distress22.02.01.0120.000470%Not Available
Retching07.01.07.0020.000437%Not Available
Rhinorrhoea22.12.03.021--
Skin disorder23.03.03.0070.000548%Not Available
Skin exfoliation23.03.07.0030.001007%Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Sleep apnoea syndrome22.02.01.013; 19.02.05.002; 17.15.05.0010.000381%
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014--
Thrombocytopenia01.08.01.0020.002138%Not Available
Thrombotic microangiopathy24.01.01.013; 20.01.07.004; 01.01.02.0060.000112%Not Available
Thrombotic thrombocytopenic purpura24.07.06.014; 23.06.01.011; 01.08.01.005--
Tongue blistering07.14.02.0140.000246%Not Available
Toothache07.09.06.0010.000571%
Tumour lysis syndrome16.32.03.002; 14.05.01.004--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Vision blurred17.17.01.010; 06.02.06.0070.002619%
Visual impairment06.02.10.0130.002071%Not Available
Vomiting07.01.07.0030.015289%
Cardiotoxicity02.11.01.009; 12.03.01.0070.000246%Not Available
Hypoacusis04.02.01.0060.000604%
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.000112%Not Available
Performance status decreased08.01.03.042--Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.008171%Not Available
General physical health deterioration08.01.03.0180.001198%Not Available
Muscle tightness15.05.03.0070.000437%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.001813%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000246%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000627%
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages